Glucocorticoid-induced osteoporosis: hope on the HORIZON. (Q46052975)

19 December 2017

title

Glucocorticoid-induced osteoporosis: hope on the HORIZON. (English)

1 reference

19 December 2017

glucocorticoid-induced osteoporosis

main subject

osteoporosis

0 references

1 reference

2

John P Bilezikian

1 reference

19 December 2017

Luigi Gennari

1

1 reference

19 December 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

19 December 2017

published in

The Lancet

1 reference

19 December 2017

volume

373

1 reference

19 December 2017

issue

9671

1 reference

19 December 2017

page(s)

1225-1226

1 reference

19 December 2017

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Transmission of human herpesvirus 8 by blood transfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960704-2

7 January 2021

10.1016/S0140-6736(09)60704-2

Identifiers

DOI

1 reference

19 December 2017

1 reference

19 December 2017